Perimeter's AI Claim Cleared a Trial. Zeta's Cleared a Paperwork Update.
- Aug 23
- 2 min read
Updated: Aug 26
Every surgical device company selling anything with a processor now calls it AI-powered.
The FDA clearance behind that label tells a far more specific story than the marketing copy does.
And the story changes completely depending on which regulatory pathway got the device to market.
The Claims Verification Ledger
A claims verification ledger does one thing.
It separates what a company says its AI does from what the FDA actually reviewed.
Every entry has three parts: the claim, quoted from the company's own announcement; the filing, meaning the regulatory pathway and what it covered; and the verdict, an assessment of how closely the two line up.
Two systems make the gap between pathways concrete.
The Trial: Perimeter's Claire OCT
Perimeter Medical Imaging markets Claire — its AI-enabled optical coherence tomography platform — for real-time surgical margin assessment during breast-conserving surgery.
Claire OCT reached the market through Premarket Approval, the FDA's most demanding device pathway.
PMA requires clinical trial data demonstrating safety and effectiveness, not just similarity to an existing device.
Perimeter's pivotal trial showed a statistically significant reduction in patients with residual cancer using the AI-assisted system.
That is a measurable clinical outcome, reviewed by the FDA, tied directly to the AI claim being marketed.
The Paperwork: Zeta Surgical Navigation
Zeta Surgical markets its Navigation System as "AI-Powered" — GPS-like cranial guidance built on computer vision, artificial intelligence, and mixed reality.
The underlying navigation technology was reviewed under a 510(k) clearance in 2023.
A second clearance followed in 2024, and it is this one that carries the "AI-Powered Navigation System" name in the company's own press release headline.
That second clearance was a Special 510(k) — the FDA pathway used for modifications to an already-cleared device, not a first-time review of new technology.
Read against the filing, the 2024 announcement expanded instrument compatibility and hospital connectivity.
It did not introduce a new AI capability the FDA reviewed that year.
Why the Pathway Is the Story
Both systems are real, cleared, and legitimately in use.
Neither company is lying about being FDA-cleared.
But "AI-powered" sitting next to a PMA and "AI-powered" sitting next to a Special 510(k) are not the same claim wearing different clothes.
One rests on clinical trial evidence tied to a specific outcome.
The other rests on a paperwork update to a device cleared for something else.
A hospital evaluating either system has no way to tell the difference from the press release alone — only from the filing.
The full Claims Verification Ledger — five systems, five FDA filings, verdict by verdict — is available now.
